MX342177B - Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica. - Google Patents

Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica.

Info

Publication number
MX342177B
MX342177B MX2014003557A MX2014003557A MX342177B MX 342177 B MX342177 B MX 342177B MX 2014003557 A MX2014003557 A MX 2014003557A MX 2014003557 A MX2014003557 A MX 2014003557A MX 342177 B MX342177 B MX 342177B
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
compounds
disease
lrrk2 kinase
lrrk2
Prior art date
Application number
MX2014003557A
Other languages
English (en)
Other versions
MX2014003557A (es
Inventor
Hoflack Jan
Blom Petra
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of MX2014003557A publication Critical patent/MX2014003557A/es
Publication of MX342177B publication Critical patent/MX342177B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a nuevos compuestos macrocíclicos y composiciones que contienen tales compuestos que actúan como inhibidores de cinasa, en particular como inhibidores de LRRK2 (Cinasa 2 de Repetición Rica en Leucina). Sin embargo, la presente invención proporciona procesos para la preparación de los compuestos descritos, así como también métodos para usarlos, por ejemplo como un medicamento o agente de diagnóstico, en particular para el tratamiento y/o diagnóstico de enfermedades caracterizadas por actividad de cinasa LRRK2 tales como trastornos neurológicos que incluyen enfermedad de Parkinson y enfermedad de Alzheimer.
MX2014003557A 2011-09-30 2012-09-28 Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica. MX342177B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2011067086 2011-09-30
PCT/IB2012/002318 WO2013046029A1 (en) 2011-09-30 2012-09-28 Macrocyclic lrrk2 kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2014003557A MX2014003557A (es) 2014-11-26
MX342177B true MX342177B (es) 2016-09-20

Family

ID=47326223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003557A MX342177B (es) 2011-09-30 2012-09-28 Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica.

Country Status (17)

Country Link
US (2) US9096609B2 (es)
EP (1) EP2760453B1 (es)
JP (1) JP6082397B2 (es)
KR (1) KR20140095477A (es)
CN (1) CN104023728B (es)
AU (1) AU2012314035B2 (es)
BR (1) BR112014007654A8 (es)
CA (1) CA2850350A1 (es)
DK (1) DK2760453T3 (es)
ES (1) ES2583477T3 (es)
HU (1) HUE029728T2 (es)
MX (1) MX342177B (es)
PL (1) PL2760453T3 (es)
PT (1) PT2760453T (es)
RU (1) RU2622104C2 (es)
UA (1) UA113186C2 (es)
WO (1) WO2013046029A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2760867T3 (en) * 2011-09-30 2016-04-11 Oncodesign Sa Macrocyclic FLT3 kinase inhibitors
CN105732639A (zh) 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
WO2014140235A1 (en) * 2013-03-15 2014-09-18 Ipsen Pharma S.A.S. Macrocyclic lrrk2 kinase inhibitors
AU2014230111A1 (en) * 2013-03-15 2015-10-29 Oncodesign S.A Macrocyclic RIP2 kinase inhibitors
KR20150133767A (ko) * 2013-03-15 2015-11-30 온코디자인 에스.에이. 거대고리 염-유도성 키나아제 억제제
CN105164136B (zh) * 2013-05-06 2017-12-22 默克专利股份公司 作为激酶抑制剂的大环化合物
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2015136073A1 (en) * 2014-03-14 2015-09-17 Oncodesign Sa Macrocyclic tgf-br2 kinase inhibitors
US10004751B2 (en) 2014-07-10 2018-06-26 The J. David Gladstone Institutes Compositions and methods for treating Dengue virus infection
MX376087B (es) 2014-09-17 2025-03-07 Oncodesign Prec Medicine Opm Inhibidores macrocíclicos de cinasa rip2.
BR112017005299A2 (pt) * 2014-09-17 2017-12-12 Ipsen Pharma Sas inibidores de lrrk2 cinase macrocíclicos
WO2016146651A1 (en) 2015-03-16 2016-09-22 Oncodesign Sa Macrocyclic activin-like receptor kinase inhibitors
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
TW201815799A (zh) * 2016-07-28 2018-05-01 美商Ｔｐ生物醫藥公司 巨環激酶抑制劑
KR101923852B1 (ko) * 2017-02-24 2018-11-29 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
TW201920197A (zh) * 2017-07-14 2019-06-01 英商葛蘭素史克智慧財產發展有限公司 化合物
CN110627812B (zh) 2018-06-25 2022-10-11 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
DK3870579T3 (da) 2018-10-22 2025-01-02 Alumis Inc Tyk2-inhibitorer og anvendelser deraf
US12178807B2 (en) 2018-11-09 2024-12-31 Xuanzhu Biopharmaceutical Co., Ltd. Macrocyclic tyrosine kinase inhibitor and uses thereof
WO2021152165A1 (en) * 2020-01-31 2021-08-05 Oncodesign S.A. Macrocyclic rip2-kinase inhibitors
MX2022013861A (es) 2020-05-06 2023-02-22 Servier Lab Nuevos inhibidores macrociclicos de la quinasa de lrrk2.
JP2024512449A (ja) * 2021-03-18 2024-03-19 レ ラボラトワール セルヴィエ 大環状ｌｒｒｋ２キナーゼ阻害剤
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
TW202330549A (zh) 2021-10-27 2023-08-01 丹麥商Ｈ 朗德貝克公司 Lrrk2抑制劑
WO2023222005A1 (zh) * 2022-05-18 2023-11-23 上海翊石医药科技有限公司 一种芳杂环类化合物及其中间体、药物组合物和用途
US20250313575A1 (en) * 2022-05-20 2025-10-09 Merck Sharp & Dohme Llc Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2025235733A1 (en) * 2024-05-09 2025-11-13 Blossomhill Therapeutics, Inc. Bis-bicycloheteroaryl macrocycles and their use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
IL111080A (en) 1993-10-01 1999-08-17 Astra Ab Method for treating a finely divided powder medicament
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
HUP0303653A3 (en) 2000-12-28 2006-05-29 Ono Pharmaceutical Co Tricyclic and heterocyclic derivative and pharmaceutical compositions containing them as the active ingredient
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
EP1697384B1 (en) * 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
ES2393926T3 (es) 2004-10-21 2013-01-02 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Gen KASPP (LRRK2), su producción y uso para la detección y tratamiento de trastornos neurodegenerativos
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
FI123725B (fi) 2005-08-01 2013-10-15 Reijo Viljanen Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP1951729B1 (en) * 2005-11-16 2014-06-25 Cell Therapeutics, Inc. Oxygen linked pyrimidine derivatives
WO2008058126A2 (en) * 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
EP2121707B1 (en) * 2006-12-20 2012-12-05 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Antiviral indoles
US7732434B2 (en) * 2007-04-20 2010-06-08 Bristol-Myers Squibb Company Macrocyclic acyl guanidines as beta-secretase inhibitors
US8318731B2 (en) * 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
EP2283024B1 (en) * 2008-03-10 2013-05-15 Janssen Pharmaceutica, N.V. 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors
DE102008019146A1 (de) 2008-04-16 2009-11-05 Airbus Deutschland Gmbh Enteisungssystem für ein Flugzeug
MX2011009807A (es) * 2009-03-19 2011-09-29 Medical Res Council Technology Compuestos.
RU2012116003A (ru) * 2009-09-21 2013-10-27 Ф.Хоффманн-Ля Рош Аг Макроциклические ингибиторы jak
US8778939B2 (en) 2009-09-29 2014-07-15 Glaxo Group Limited Compounds
KR101953210B1 (ko) * 2011-05-19 2019-02-28 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ 단백질 키나아제 억제제로서의 대환식 화합물
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
DK2760867T3 (en) * 2011-09-30 2016-04-11 Oncodesign Sa Macrocyclic FLT3 kinase inhibitors

Also Published As

Publication number Publication date
JP6082397B2 (ja) 2017-02-15
US20140206683A1 (en) 2014-07-24
PL2760453T3 (pl) 2016-11-30
HK1199838A1 (en) 2015-07-24
US9096609B2 (en) 2015-08-04
CN104023728A (zh) 2014-09-03
UA113186C2 (xx) 2016-12-26
AU2012314035A1 (en) 2014-05-15
RU2622104C2 (ru) 2017-06-13
HUE029728T2 (en) 2017-03-28
WO2013046029A1 (en) 2013-04-04
CA2850350A1 (en) 2013-04-04
ES2583477T3 (es) 2016-09-21
AU2012314035B2 (en) 2016-12-15
US9370520B2 (en) 2016-06-21
US20150290198A1 (en) 2015-10-15
PT2760453T (pt) 2016-08-02
RU2014117515A (ru) 2015-11-10
EP2760453B1 (en) 2016-05-25
MX2014003557A (es) 2014-11-26
KR20140095477A (ko) 2014-08-01
BR112014007654A2 (pt) 2018-04-17
EP2760453A1 (en) 2014-08-06
JP2014528405A (ja) 2014-10-27
BR112014007654A8 (pt) 2018-06-12
CN104023728B (zh) 2016-11-02
DK2760453T3 (en) 2016-08-15

Similar Documents

Publication Publication Date Title
MX342177B (es) Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica.
MX2017003470A (es) Inhibidores macrociclicos de cinasa lrrk2.
SG179120A1 (en) Novel compounds
WO2012162254A8 (en) Inhibitors of lrrk2 kinase activity
MX2012001070A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos.
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
EA025086B9 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
CL2012001073A1 (es) Compuestos derivados de pirido[4,3-d]pirimidin-5-ona, sus composiciones farmaceuticas y su uso como inhibidores de quinasa para tratar asma, epoc, colitis ulcerante, bronquitis, lupus, cancer de mamas, enfermedad de alzheimer, enfermedad de parkinson, osteoporosis, esclerosis multiple, diabetes, trastornos oculares, restenosis, enfermedades inflamatorias.
WO2012048129A3 (en) Inhibitors of polo-like kinase
MX2009004908A (es) Compuestos quimicos.
PH12015500211B1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
MX2016009893A (es) Compuestos.
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
MX2009010407A (es) Derivados fluorados de deferiprona.
TN2015000018A1 (en) 5-ht3 receptor antagonists
MX2015012528A (es) Inhibidores macrociclicos de cinasa inducibles por sal.
MX2015012526A (es) Inhibodores macrociclicos de cinasa rip2.
MX2014006433A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2.
MX2009007889A (es) Derivados de 3-cinnolincarboxamida y su uso para el tratamiento del cancer.
MY186523A (en) Macrocyclic rip2 kinase inhibitors
TN2012000191A1 (en) Quinuclidine compounds as alpha-7nicotinic acetylcholine receptor ligands
EA201591021A1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
PH12014501051A1 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Legal Events

Date Code Title Description
FG Grant or registration